

Randomised controlled trial of standard EndoVenous Laser Ablation (EVLA) versus standard EVLA with below-knee foam sclerotherapy versus above and below-knee EVLA for varicose veins

Submission date 05/07/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 26/07/2007	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 05/05/2011	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Mr Nadarajah Theivacumar

Contact details
Leeds Vascular Institute
Leeds General Infirmary
Great George Street
Leeds
United Kingdom
LS1 3EX
+44 (0)7940 774550
nadacumar@yahoo.co.uk

Additional identifiers

Study information

Scientific Title

Acronym

Leeds EVLA technique trial

Study objectives

Modified techniques reduces requirement of delayed foam sclerotherapy and provides better clinical outcome.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Leeds (West) research ethics committee, at Leeds General Infirmary on 21/09/2005 (ref: 05/Q1205/187)

Primary study design

Interventional

Study design

Randomised controlled trial (not blinded)

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Varicose veins

Interventions

Two modified techniques are compared with standard EVLA technique:

Group A: the standard practice of EVLA (laser ablation of above-knee Great Saphenous Vein [GSV]) considered as control

Group B: modification 1 - where GSV was ablated (EVLA) both above and below knee

Group C: modification 2 - where above knee GSV was ablated by EVLA and below knee GSV was chemically ablated using foam sclerotherapy at the same time

Group 1 - standard EVLA alone:

This uses an 810 nm bare-tipped, pulsed laser (Diomed Inc.) at a power of 12 watts. The standard technique for EVLA will be used employing a laser density of 5 pulse/cm. Delayed foam sclerotherapy up to 5 ml of 0.2-1% STD was used as required at the follow up clinic visit/s.

Group 2 - standard EVLA and on table foam sclerotherapy:

The same EVLA technique as for group 1 was used except that the GSV was cannulated below-knee (mid-calf) and a 70 cm sheath inserted. The GSV was ablated (EVLA) to the level of the knee joint following which 5 ml 1% STD (2 ml 1% STD, 3 ml air) will be injected into the below knee GSV via the sheath as it was withdrawn. Delayed foam sclerotherapy up to 5 ml of 0.2-1% STD was also be used as required at the follow up clinic visit/s.

Group 3 - above and below-knee EVLA:

The GSV was cannulated below-knee (mid-calf) and the whole length of the GSV ablated using the standard EVLA technique. Delayed foam sclerotherapy up to 5 ml of 0.2-1% STD was also used as required at the follow up clinic visit/s.

Following this primary treatment patients were followed up at 1, 6, and 12 weeks and following data were obtained at each visit:

1. At 1 week:

- 1.1. Daily Visual Analogue Score for pain
- 1.2. Analgesia diary
- 1.3. Time to normal activity - time to return to work
- 1.4. Assessment of post-treatment complications
- 1.5. Duplex assessment of GSV and deep veins for evidence of Deep Vein Thrombosis (DVT)

2. At 6 weeks:

- 2.1. Outstanding data from week 1
- 2.2. Aberdeen Vein Questionnaire (disease-specific quality of life measure)***
- 2.3. Late complications
- 2.4. Time of return to work if greater than 1 week
- 2.5. Injection sclerotherapy as required in all patients
- 2.6. Duplex assessment of GSV

3. At 12 weeks:

- 3.1. Any outstanding data (as above)
- 3.2. Duplex Ultrasound Assessment
- 3.3. Aberdeen Vein Questionnaire (disease-specific quality of life measure)***
- 3.4. EuroQol questionnaire
- 3.5. Patient satisfaction
- 3.6. Number of sessions of injection Sclerotherapy as required***
- 3.7. Duplex assessment

*** = Primary endpoint measurements

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Sclerotherapy requirement at follow up: disease specific quality of life improvement measured by Aberdeen varicose vein severity score.

Key secondary outcome(s)

1. Post-procedure pain: patient analgesia diary
2. Cosmesis: as scored by the patient
3. Complication rates: wound infection, haematoma, nerve injury, DVT
4. Patient satisfaction

Completion date

15/05/2007

Eligibility

Key inclusion criteria

Patients with primary varicose veins in the leg due to isolated incompetent sapheno-femoral junction and great saphenous vein reflux both above and below knee segments.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

1. Recurrent varicose veins
2. Patients with reflux in other axial veins
3. Patients with varicose veins only in thigh
4. Patients who has no reflux in below-knee segment of great saphenous vein

Date of first enrolment

10/11/2005

Date of final enrolment

15/05/2007

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Leeds Vascular Institute

Leeds

United Kingdom

LS1 3EX

Sponsor information

Organisation

Leeds General Infirmary (UK)

ROR

<https://ror.org/04hrjej96>

Funder(s)

Funder type

Research organisation

Funder Name

Leeds Vascular Institute (UK) - Research Fund

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/07/2008		Yes	No